Maternity and multiple sclerosis in the context of disease-modifying treatment

Abstract

Multiple sclerosis is a chronic inflammatory degenerative disease of the central nervous system, which often requires treatment on diagnosis. Given its dominating prevalence among women of childbearing age, the increasing availability and new types of disease-modifying drugs, at the beginning of treatment consideration should be given to a patient’s maternity plans. Pregnancy, as a physiological condition affecting the activity of multiple sclerosis, can be regarded as induction of pharmacotherapy or as a component thereof. This review discusses the problem of maternity in patients with multiple sclerosis, with particular emphasis on optimizing disease-modifying treatment.

Piśmiennictwo

1. Van der Kop ML, Pearce MS, Dahlgren L, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011;70(1):41-50.

2. Alwan S, Yee IM, Dybalski M, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 2013;19(3):351-8.

3. Roux T, Courtillot C, Debs R, et al. Fecundity in women with multiple sclerosis: an observational mono-centric study. J Neurol 2015;262(4):957-60.

4. Manouchehri E, Najafi TF, Saeedi M, et al. Menstrual pattern in women with multiple sclerosis. IJOGI 2017;19(38):42-7.

5. Vukusic S, Durand-Dubief F, Benoit A, et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler 2015;21(7):953-5.

6. Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012;83(8): 796-802.

7. Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014;20(6):739-46.

8. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127 (Pt 6):1353-60.

9. Buraga I, Popovici RE. Multiple sclerosis and pregnancy: current considerations. ScientificWorldJournal 2014;2014:513160.

10. Confavreux C, Hutchinson M, Hours MM, et al. Pregnancy in Multiple Sclerosis Group. Rate of pregnancy related relapse in multiple sclerosis. New Engl J Med 1998;339(5):285-91.

11. Borisow N, Paul F, Dörr J. Optimal management of multiple sclerosis during pregnancy: current perspectives. Degener Neurol Neuromuscul Dis 2014;4:111-20.

12. Finkelsztejn A, Brooks JB, Paschoal FM Jr, et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 2011;118(7):790-7.

13. Karp I, Manganas A, Sylvestre MP, et al. Does pregnancy alter the long-term course of multiple sclerosis? Ann Epidemiol 2014;24(7):504-8.

14. Ramagopalan S, Yee I, Byrnes J, et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012;83:793-5.

15. D’hooghe MB, Nagels G, Uitdehaag BMJ. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 2010;81(1):38-41.

16. Masera S, Cavalla P, Prosperini L, et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler 2015;21(10):1291-7.

17. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases 2015;3(7):545-55.

18. Hellwig K, Rockhoff M, Herbstritt S, et al. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol 2015;72(10):1132-8.

19. Wundes A, Pebdani RN, Amtmann D. What do healthcare providers advise women with multiple sclerosis regarding pregnancy? Mult Scler Int 2014;2014:819216.

20. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012;5(5):247-53.

21. Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2013;115(2):154-9.

22. Bernick SJ, Kane S. Drug transfer to the fetus and to the breastfeeding infant: what do we know? Curr Drug Deliv 2012;9(4):350-5.

23. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005;65(6):807-11.

24. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005;65(6):802-6.

25. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009;15(9):1037-42.

26. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 2010;75(20):1794-802.

27. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79(11):1130-5.

28. Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler J 2011;17(4):423-30.

29. Richman S, Wallace K, Liu S, et al. Final Results from the AVONEX® (Intramuscular Interferon Beta-1a) Pregnancy Exposure Registry. Neurology 2012;78(1).

30. Romero RS, Lünzmann C, Bugge JP. Pregnancy outcomes in patients exposed to interferon beta-1b. J Neurol Neurosurg Psychiatry 2015;86(5):587-9.

31. Coyle PK, Sinclair SM, Scheuerle AE, et al. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open 2014;4(5):e004536.

32. Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis – A Prospective Cohort Study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler J 2016;22(6):801-9.

33. Borisow N, Döring A, Pfueller CF, et al. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J 2012;3(1):9.

34. Tsui A, Lee MA. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol 2011;23(6):435-9.

35. Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler 2016;22(6):810-6.

36. Neudorfer O, Baruch P, Pery S, et al. Effect of exposure to branded glatiramer acetate during pregnancy on rates of pregnancy loss. ECTRIMS 2016.

37. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 2010;257(12):2020-3.

38. Prescribing information for pharmacologic therapies for MS. Europe – Summaries of Product Characteristics, USA, full Prescribing Information downloaded from sponsors’ product websites; http://www.medicines.org.uk/emc/.

39. Alroughani R, Altintas A, Al Jumah M, et al. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int 2016;2016:1034912.

40. Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler J 2015;21(2):198-205.

41. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler J 2011;17(8):958-63.

42. Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurology 2014;71(7):891-5.

43. Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014;82(8):674-80.

44. Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther 2014;3(2):133-8.

45. Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther 2015;4(2):93-104.

46. Oh J, Achiron A, Chambers C, et al. Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program. Neurology 2016;86(16 Suppl):S24.008.

47. De Santis M, Straface G, Cavaliere AF, et al. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology 2007;28(3):696-7.

48. Hellwig K, Schimrigk S, Chan A, et al. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 2011;307(1-2):164-5.

49. Gregg C, Shikar V, Larsen P, et al. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 2007;27(8):1812-23.

Do góry